Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access
- 1 March 2022
- journal article
- research article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 41 (3) , 383-389
Abstract
There is a tremendous public health need to identify potentially lethal cancers at earlier stages, when there is a greater chance for improved survival. Although in the US there are currently screening recommendations for only five cancers (breast, colorectal, cervical, lung, and prostate), new tests can screen for up to fifty cancers simultaneously based on a simple blood draw. However, these multicancer screening tests (also called “liquid biopsy” tests) will also present challenges to payers because of intrinsic features of the tests and the complexity of payer coverage assessments for screening tests. We describe these considerations while also offering potential solutions that can inform payers’ decision making if these tests prove to be beneficial.Keywords
This publication has 19 references indexed in Scilit:
- Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest GroupValue in Health, 2020
- Could liquid biopsies help deliver better treatment?Nature, 2020
- Applications of liquid biopsies for cancerScience Translational Medicine, 2019
- Universal cancer screening: revolutionary, rational, and realizablenpj Precision Oncology, 2018
- The value of cell‐free DNA for molecular pathologyThe Journal of Pathology, 2018
- The dawn of the liquid biopsy in the fight against cancerOncotarget, 2017
- Evidence-Based Clinical Prevention in the Era of the Patient Protection and Affordable Care ActJAMA, 2015
- Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)Health Policy, 2015
- The National Emphysema Treatment Trial (NETT): A Study in Agency CollaborationProceedings of the American Thoracic Society, 2008
- Revisting wilson and Jungner in the genomic age: a review of screening criteria over the past 40 yearsBulletin of the World Health Organization, 2008